

Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia

Pavelka, Karel

Burgos-Vargas, Ruben

Miranda, Pedro

Guzman, Renato

Yen, Jeng Hsien

Izzi, Mustafa Al

Szekanecz, Zoltan

Tang, Boxiong

Szumski, Annette

Kotak, Sameer

Bananis, Eustratios

Koenig, Andrew S.

Mahgoub, Ehab Y.

Rahman, Mahboob U.

© 2014 Future Medicine Ltd. Aims: We compared etanercept 50 mg once weekly

(ETN50)/methotrexate versus etanercept 25 mg (ETN25)/methotrexate or biologic-free methotrexate

after response to ETN50/methotrexate in moderate rheumatoid arthritis patients from central/eastern

Europe, Latin America and Asia. Methods: In a 36-week induction phase, methotrexate-resistant

patients received ETN50/methotrexate. In a 52-week, double-blind phase, patients who achieved

sustained Disease Activity Score in 28 joints low disease activity (LDA) were randomized to

ETN50/methotrexate, ETN25/methotrexate or methotrexate. Results: Sustained Disease Activity

Score in 28 joints LDA was achieved in 85% at week 36. LDA was achieved in 83, 81 and 50% with

ETN50/methotrexate, ETN25/methotrexate and methotrexate and remission in 66, 61 and 31%,

respectively, at week 88 ($p < 0.0001$). Conclusion: Etanercept/methotrexate therapy for 36 weeks

effectively induced response in this moderate rheumatoid arthritis subpopulation.